| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | NRF2 |
| Entrez GeneID | 4780 |
| clone | 1A6G6 |
| WB Predicted band size | 67.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human NFE2L2 (AA: 356-589) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于NFE2L2(NRF2)抗体的代表性文献概览，供参考：
---
1. **文献名称**：*"Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system"*
**作者**：Suzuki T, et al.
**摘要**：研究NFE2L2与Keap1蛋白的相互作用及泛素-蛋白酶体系统对NRF2的降解调控，利用NFE2L2抗体通过免疫共沉淀(Co-IP)和Western blot验证了Keap1介导的NRF2泛素化过程。
2. **文献名称**：*"Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer"*
**作者**：Shibata T, et al.
**摘要**：通过免疫组织化学(IHC)和Western blot分析胆囊癌中NFE2L2的核易位及表达水平，发现Keap1基因突变导致NRF2持续激活，并与化疗耐药相关。
3. **文献名称**：*"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis"*
**作者**：DeNicola GM, et al.
**摘要**：揭示致癌信号通过激活NRF2促进活性氧(ROS)清除以支持肿瘤生长，研究中采用NFE2L2抗体进行ChIP-seq分析，证实NRF2直接结合抗氧化基因启动子区域。
---
**备注**：以上文献均聚焦于NFE2L2在氧化应激和癌症中的功能机制，抗体应用场景包括蛋白质互作验证(Co-IP)、表达水平检测(WB/IHC)及靶基因调控分析(ChIP-seq)。建议通过PubMed或Web of Science检索具体DOI以获取全文。
The NFE2L2 antibody is a crucial tool for studying the nuclear factor erythroid 2-related factor 2 (NFE2L2. also known as Nrf2), a master regulator of cellular antioxidant responses. Nrf2 is a transcription factor that binds to antioxidant response elements (AREs) in the promoter regions of target genes, activating their expression under oxidative or electrophilic stress. These genes encode detoxifying enzymes (e.g., NAD(P)H quinone dehydrogenase 1), glutathione synthesis proteins, and phase II drug-metabolizing enzymes, which collectively protect cells against oxidative damage, inflammation, and carcinogenesis.
NFE2L2 antibodies are widely used in research to detect Nrf2 protein levels, localization, and activity in various disease models, including cancer, neurodegenerative disorders, and metabolic syndromes. They are employed in techniques like Western blotting, immunohistochemistry, immunofluorescence, and chromatin immunoprecipitation (ChIP) to study Nrf2's regulation by KEAP1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and degradation under basal conditions. Dysregulation of the Nrf2-KEAP1 pathway is implicated in chemoresistance, chronic inflammation, and tumor progression, making NFE2L2 antibodies essential for exploring therapeutic strategies targeting this pathway. Researchers also use these antibodies to evaluate the efficacy of Nrf2 activators (e.g., sulforaphane) in preclinical studies.
×
